Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma, will begin sales of its Test Kits for the rapid identification of Nontuberculous Mycobacterium (NTM).
"The Designer Diagnostics NTM Test Kits provide the medical community with a fast, reliable, and easy method for testing HIV/AIDS patients for non-tubercular mycobacterium such as M. Avium, Nocardia and Pseudomonas," explained Dr. Robert Ollar, Chairman of the Scientific Advisory Board at Designer Diagnostics. "The Test Kits require no special equipment or refrigeration, allowing them to be easily used in the field," he concluded.
The product launch was made during a recent CME (Continuing Medical Education) Conference, which focused on the technology offered by Designer Diagnostics and the coming pandemic of NTM diseases. Dr. P. Narang, a noted microbiologist and the Dean of The Mahatma Gandhi Institute of Medical Science in Sevagram, India, hosted the Conference, which included guest lecturers from the World Health Organization (WHO), Grant Medical College, the National JALMA Institute for Leprosy and Other Mycobacterial Diseases, JJ Hospital Mumbai, the Mahatma Gandhi Institute, and Designer Diagnostics Inc.
"The NTM Test Kits address a huge market for Designer Diagnostics," explained Neil Roth, President of Designer Diagnostics. "NTMs and Tuberculosis (TB) account for the majority of deaths in HIV/AIDS patients. The occurrence of NTMs is dramatically increasing as the number of HIV/AIDS and other immuno-suppressed patients increase. There are currently more than 40 million people who should be tested for these diseases," he concluded.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Beginning sales of the Designer Diagnostics' Test Kits for the identification of NonTuberculous Mycobacterium should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.